BioPharm International - October 2021

BioPharm-October 2021-Regulatory-Sourcebook

Issue link: https://www.e-digitaleditions.com/i/1420307

Contents of this Issue

Navigation

Page 2 of 33

Accelerating Your Path To IND 12 MONTHS www.wuxibiologics.com Our highly vetted, single-source, expedited biologics platform: • Speeds your time-to-clinic • Removes multiple vendor transitions • Reduces audits and transactions • Provides single-point project management • Enabled multiple anti-COVID-19 mAbs to enter the clinic in record breaking time Quality. Expertise. Performance. Speed. Our accelerated DNA to IND platform is built upon these cornerstones. This seamless, integrated process utilizes our U.S. FDA, EMA, NMPA, ANVISA, PDMA and HSA approved quality systems and facilities. Our proven platform has expedited over 200 INDs in just the last few years. We can deliver success to your drug development efforts. Let's Get Started. Industry Leading DNA to IND Timelines < 6 MONTHS

Articles in this issue

Links on this page

Archives of this issue

view archives of BioPharm International - October 2021 - BioPharm-October 2021-Regulatory-Sourcebook